David A Reardon

David A Reardon

UNVERIFIED PROFILE

Are you David A Reardon?   Register this Author

Register author
David A Reardon

David A Reardon

Publications by authors named "David A Reardon"

Are you David A Reardon?   Register this Author

100Publications

3098Reads

43Profile Views

Molecular targeted therapy of glioblastoma.

Cancer Treat Rev 2019 Nov 11;80:101896. Epub 2019 Sep 11.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.101896DOI Listing
November 2019

An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning.

Neurosurgery 2019 Oct 5. Epub 2019 Oct 5.

Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery, Brigham and Women's Hospital, School of Medicine, Harvard University, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuros/nyz403DOI Listing
October 2019

Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis.

J Neurosurg 2019 Oct 25:1-11. Epub 2019 Oct 25.

1Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2019.6.JNS19972DOI Listing
October 2019

Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas.

Neuro Oncol 2019 Sep 20. Epub 2019 Sep 20.

Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz168DOI Listing
September 2019

Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model.

Theranostics 2019 14;9(21):6284-6299. Epub 2019 Aug 14.

Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women's Hospital; Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.35892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735504PMC
August 2019

Efficacy and safety of immune checkpoint blockade for brain metastases.

CNS Oncol 2019 Jun 11;8(2):CNS33. Epub 2019 Mar 11.

Harvard Medical School, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/cns-2018-0018
Publisher Site
http://dx.doi.org/10.2217/cns-2018-0018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713022PMC
June 2019

Survival and prognostic factors in surgically treated brain metastases.

J Neurooncol 2019 Jun 16;143(2):359-367. Epub 2019 Apr 16.

Department of Neurosurgery, Computational Neuroscience Outcomes Center, Brigham and Women's Hospital, 60 Fenwood Rd., 4th Floor, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-019-03171-6
Publisher Site
http://dx.doi.org/10.1007/s11060-019-03171-6DOI Listing
June 2019

The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Clin Cancer Res 2019 Apr 11;25(8):2656-2663. Epub 2019 Jan 11.

Department of Pathology, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467794PMC
April 2019

Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.

AJR Am J Roentgenol 2018 12 17;211(6):1342-1347. Epub 2018 Oct 17.

1 Department of Radiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.

View Article

Download full-text PDF

Source
https://www.ajronline.org/doi/10.2214/AJR.18.19988
Publisher Site
http://dx.doi.org/10.2214/AJR.18.19988DOI Listing
December 2018

Pseudoprogression: fact or wishful thinking in neuro-oncology?

Lancet Oncol 2018 12;19(12):1561-1563

Department of Neurology & Brain Tumor Center, University Hospital Zurich, CH-8091 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30654-5DOI Listing
December 2018

PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.

Neurology 2018 10 31;91(14):e1355-e1359. Epub 2018 Aug 31.

From the Laura and Isaac Perlmutter Cancer Center (S.C.K.), Brain Tumor Center, NYU Langone Medical Center, New York; Dana-Farber Cancer Institute (L.P.C., D.H., M.R., L.N., E.Q.L., D.A.R., P.Y.W.), Center for Neuro-Oncology; and Department of Radiology (R.H., P.U.), Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006283DOI Listing
October 2018

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Eur J Cancer 2018 09 20;101:95-104. Epub 2018 Jul 20.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.06.029DOI Listing
September 2018

Immunotherapy for glioblastoma: going viral.

Nat Med 2018 08;24(8):1094-1096

Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-018-0142-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443579PMC
August 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Cancer Cell 2018 07;34(1):163-177.e7

Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.06.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424337PMC
July 2018

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.

Clin Cancer Res 2018 06 6;24(11):2574-2584. Epub 2018 Mar 6.

Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-2954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800093PMC
June 2018

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

J Neurooncol 2018 May 8;138(1):163-171. Epub 2018 Feb 8.

Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-018-2786-8
Publisher Site
http://dx.doi.org/10.1007/s11060-018-2786-8DOI Listing
May 2018

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

J Neurooncol 2018 Apr 21;137(2):349-356. Epub 2017 Dec 21.

Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2724-1DOI Listing
April 2018

Concepts for Immunotherapies in Gliomas.

Semin Neurol 2018 02 16;38(1):62-72. Epub 2018 Mar 16.

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0037-1620274DOI Listing
February 2018

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Neuro Oncol 2018 01;20(2):249-258

Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777496PMC
January 2018

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Neuro Oncol 2018 01;20(2):259-267

The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W., J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California San Francisco, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.P., J.H., R.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777491PMC
January 2018

Modeling tumor immunity of mouse glioblastoma by exhausted CD8 T cells.

Sci Rep 2018 01 9;8(1):208. Epub 2018 Jan 9.

Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-18540-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760520PMC
January 2018

High-grade Gliomas.

Continuum (Minneap Minn) 2017 Dec;23(6, Neuro-oncology):1548-1563

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CON.0000000000000554DOI Listing
December 2017

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Neuro Oncol 2017 Nov;19(12):1688-1697

Departments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://academic.oup.com/neuro-oncology/article/19/12/1688/38
Publisher Site
http://dx.doi.org/10.1093/neuonc/nox092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716072PMC
November 2017

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.

Nat Rev Clin Oncol 2017 Nov 4;14(11):695-707. Epub 2017 Jul 4.

Austin Health and Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.95DOI Listing
November 2017

Immunotherapy for glioblastoma: on the sidelines or in the game?

Discov Med 2017 11;24(133):201-208

Department of Neurosurgery, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
November 2017

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Neuro Oncol 2017 Aug;19(8):1119-1126

Tel-Aviv Sourasky Medical Center, Tel-Aviv University; European Organization for Research and Treatment of Cancer, Brussels (EORTC); National Institutes of Health (M.R.M.); University of Alabama at Birmingham; Princess Margaret Cancer Centre, University of Toronto; Lausanne University Hospital; NRG Oncology Statistics and Data Management Center; Odette Cancer Centre and Sunnybrook Health Sciences Centre, University of Toronto; Samsung Medical Center, Sungkyunkwan University School of Medicine; Edinburgh Cancer Centre; Mayo Clinic; Robert-Janker Clinic at the University of Bonn Medical Centre, and MAASTRO clinic, GROW School for Oncology, Maastricht University Medical Centre; Miami Cancer Institute; Erasmus University Hospital; Dana-Farber Cancer Institute and Harvard Medical School; University of Zurich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570239PMC
August 2017

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Neuro Oncol 2017 Jul;19(7):965-975

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of Neurology, Northwestern University, Chicago, Illinois; Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois; Department of Medical Oncology, Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas; Department of Radiation Oncology, The University of Texas M.D.Anderson Cancer Center, Houston, Texas; AbbVie Inc., North Chicago, Illinois; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570193PMC
July 2017

Immunomodulation for glioblastoma.

Curr Opin Neurol 2017 06;30(3):361-369

aCenter for Neuro-Oncology bDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts cDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000451DOI Listing
June 2017

Angiogenesis inhibitors in tackling recurrent glioblastoma.

Expert Rev Anticancer Ther 2017 Jun 2;17(6):507-515. Epub 2017 May 2.

b Center for Neuro-Oncology , Dana-Farber Cancer Institute /Brigham and Women's Cancer Center , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1322903DOI Listing
June 2017

Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Nat Rev Neurol 2017 Jun 12;13(6):363-374. Epub 2017 May 12.

Department of Neurosurgery, Duke University Medical Center, 200 Trent Drive, Duke South, Blue Zone, 1st Floor, Room 1554, Durham 27710, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2017.64DOI Listing
June 2017

The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Semin Immunopathol 2017 02 30;39(2):225-239. Epub 2017 Jan 30.

Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, 32605, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00281-016-0616-7
Publisher Site
http://dx.doi.org/10.1007/s00281-016-0616-7DOI Listing
February 2017

Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.

Neuro Oncol 2017 01 26;19(1):109-117. Epub 2016 Jun 26.

Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts (B.Z., K.C., R.Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., K.L.L.); Department of Pathology, Harvard Medical School, Boston, Massachusetts (S.R., K.L.L.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (S.R., K.L.L.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts(S.R., D.A.R., K.L.L., P.Y.W.); Harvard Radiation Oncology Program, Boston, Massachusetts (S.T.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (W.L.B.); Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (D.A.R., P.Y.W.); Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (B.M.A.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193019PMC
January 2017

Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.

Neuro Oncol 2016 12 4;18(12):1680-1687. Epub 2016 May 4.

Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts (K.C., B.Z., R.R., D.S., N.W., R.Y.H.); Department of Radiology, College of Physicians and Surgeons, Columbia University, New York, New York (X.G., M.Z., B.Z.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (D.A.R., P.Y.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693191PMC
December 2016

The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR.

J Mol Diagn 2016 11 15;18(6):864-871. Epub 2016 Sep 15.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2016.06.009DOI Listing
November 2016

Adult brainstem gliomas.

Cancer 2016 09 21;122(18):2799-809. Epub 2016 Jun 21.

Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29920DOI Listing
September 2016

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

Neuro Oncol 2016 06 21;18(6):849-54. Epub 2016 Feb 21.

Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., M.L.R., B.M.A., N.D.A., L.D., J.S., D.L., S.F.R., J.P., K.H.S., S.C.G., S.H., P.Y.W.); Harvard Medical School, Boston, Massachusetts (E.Q.L., E.T.W., D.A.R., A.D.N., L.N., M.L.R., B.M.A., N.D.A., P.Y.W.); Massachusetts General Hospital, Boston, Massachusetts (A.M.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); University of California San Diego, La Jolla, California (S.K.); Beth Israel Deaconess Medical Center, Boston, Massachusetts (E.T.W.); Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (C.E.F.); Geisel School of Medicine at Dartmouth, Hanover, New Hampshire (C.E.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864265PMC
June 2016

Checkpoint inhibition in meningiomas.

Immunotherapy 2016 06;8(6):721-31

Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2016-0017DOI Listing
June 2016

Glioblastoma in the elderly: making sense of the evidence.

Neurooncol Pract 2016 Jun 1;3(2):77-86. Epub 2015 Sep 1.

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada (M.M., N.L.); Neurology Clinic and National Center for Tumor Disease and Neurology Clinic, Heidelberg University Medical Center and DKFZ, Heidelberg, Germany (W.W); Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA(D.A.R.); Department of Advanced Home Care and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden (A.M.); Department of Medical Oncology, Prince of Wales Hospital, Randwick NSW, Australia (E.H.); Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, Zürich, Switzerland (M.W.); Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada (J.R.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nop/npv027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668261PMC
June 2016

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

Neuro Oncol 2016 05 28;18(5):649-55. Epub 2016 Jan 28.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (M.A., P.H.M., R.B., M.L.L., S.H.R., R.D.F., K.L.L., A.H.L., S.S.); Department of Pathology, King Fahad Medical City, Riyadh, Saudi Arabia (M.A.); King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia (M.A.); Harvard Medical School, Boston, Massachusetts (M.A., A.A.A., D.D.-S., P.K.B., D.A.R., P.Y.W., O.A.-M., S.H.R., R.D.F., K.L.L., A.H.L., B.M.A., I.F.D., R.B., S.S.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (W.L.B., O.A.-M., I.F.D.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (A.A.A., B.M.A.); Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts (P.K.A.); Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts (D.D.-S.); Center for Cancer Genomic Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts (A.R.T., P.V.H.); Department of Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts (P.K.B.); Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R., P.Y.W, R.B.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (K.L.L., R.B.); Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA (S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827048PMC
May 2016

Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?

Immunotherapy 2015 23;7(6):603-6. Epub 2015 Jun 23.

Center of Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, G4200, 44 Binney St, Boston MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.15.39DOI Listing
April 2016

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

J Clin Oncol 2016 Mar 19;34(7):731-9. Epub 2016 Jan 19.

Caroline Happold, Patrick Roth, Roger Stupp, and Michael Weller, University Hospital Zurich; Monika Hegi, University Hospital Lausanne, Switzerland; Thierry Gorlia, EORTC Data Centre, Brussels, Belgium; Olivier Chinot, Aix-Marseille University, Marseille, France; Mark R. Gilbert, The University of Texas MD Anderson Cancer Center, Houston, TX; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Wolfgang Wick, University of Heidelberg & German Cancer Research Center, Heidelberg, Germany; Stephanie L. Pugh, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Timothy Cloughesy, UCLA Neuro-Oncology Program, Los Angeles, CA; David A. Reardon, Dana-Farber Cancer Institute, Boston, MA; James R. Perry, University of Toronto, Toronto, Ontario, Canada; and Minesh P. Mehta, University of Maryland, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.6563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070573PMC
March 2016

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.

Neuro Oncol 2016 Feb 30;18(2):269-74. Epub 2015 Aug 30.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (A.A.A., M.C.H., N.D.A., B.M.A.); Department of Pathology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (M.A., K.L.L., A.H.L., S.S.); Department of Neurosurgery, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (W.L.B., O.A-M., I.F.D.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (E.Q.L., L.N., M.L.R., A.D.N., D.A.R., P.Y.W., R.B.).

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/nov177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724184PMC
February 2016

Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment.

Nat Rev Neurol 2016 Feb 18;12(2):69-70. Epub 2016 Jan 18.

Centre for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Centre, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2015.242DOI Listing
February 2016

Adult Atypical Teratoid/Rhabdoid Tumors.

World Neurosurg 2016 Jan 4;85:197-204. Epub 2015 Sep 4.

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2015.08.076DOI Listing
January 2016

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Curr Treat Options Oncol 2015 Nov;16(11):54

Dana-Farber Cancer Institute, G4200, 44 Binney St, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0371-3DOI Listing
November 2015

Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.

Neuro Oncol 2015 Nov;17 Suppl 7:vii32-vii40

Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (D.A.R.); Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (D.A.R.); Neurology Clinic and National Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (M.R.G.); Neurology Clinic and National Center for Tumor Diseases, University of Heidelberg and German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W); Brain Tumor Program, Department of Neurosurgery, University of California Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, California (L.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625894PMC
November 2015

Multicentric Low-Grade Gliomas.

World Neurosurg 2015 Oct 22;84(4):1045-50. Epub 2015 May 22.

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2015.05.021DOI Listing
October 2015

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.

Oncotarget 2015 Oct;6(32):34030-7

Clinical Research Unit, Montreal Neurological Institute and Hospital, McGill University Health Center, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741824PMC
October 2015

Brachytherapy in the treatment of recurrent aggressive falcine meningiomas.

J Neurooncol 2015 Sep 8;124(3):515-22. Epub 2015 Aug 8.

Department of Neurosurgery, Brigham and Women's Hospital, and Children's Hospital, Harvard Medical School (HMS), 15 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1873-3DOI Listing
September 2015

Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Nat Rev Neurol 2015 Sep 11;11(9):504-14. Epub 2015 Aug 11.

Division of Neurosurgery, 220 Sands Building, Research Drive, Duke University School of Medicine, Durham, NC 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2015.139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782584PMC
September 2015

Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.

Int J Radiat Oncol Biol Phys 2015 Jun 1;92(2):384-9. Epub 2015 Apr 1.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.01.017DOI Listing
June 2015

A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Invest New Drugs 2015 Jun 17;33(3):671-8. Epub 2015 Apr 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0234-6DOI Listing
June 2015

One size should not fit all: advancing toward personalized glioblastoma therapy.

Discov Med 2015 Jun;19(107):471-7

Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
June 2015